Skip to main content
Enter the terms you wish to search for.
Select Search Option
This Site
All WCM Sites
Directory
Menu
Weill Cornell Medicine
Care
Discover
Teach
Jill Roberts Center for Inflammatory Bowel Disease
Explore this Website
Home
About Us
Toggle About Us menu options
Clinical Staff
Research Staff
Contact Us
Newsworthy
Toggle Newsworthy menu options
News and Announcements
Patient Care
Toggle Patient Care menu options
Clinical Services
FAQs
For Your Visit
COVID-19 Information
Nutrition Science
Toggle Nutrition Science menu options
Nutrition FAQs
Food Intolerances
News in IBD Nutrition
Research and Clinical Trials
Toggle Research and Clinical Trials menu options
Clinical Trials
Publications
Weill Cornell Medicine
Care
Discover
Teach
Home
About Us
Newsworthy
Patient Care
Nutrition Science
Research and Clinical Trials
Home
Publications
Publications
Clinical Trials
Publications
Publications
Found 7 results
Author
Title
[
Type
]
Year
Filters:
Keyword
is
Adult
and
Author
is
Scherl, Ellen J
[Clear All Filters]
Journal Article
Lukin DJ
,
Kumar A
,
Hajifathalian K
,
Sharaiha RZ
,
Scherl EJ
,
Longman RS
. 2020.
Baseline Disease Activity and Steroid Therapy Stratify Risk of COVID-19 in Patients With Inflammatory Bowel Disease.
.
Gastroenterology. 159(4):1541-1544.e2.
DeFilippis EM
,
Barfield E
,
Leifer D
,
Steinlauf A
,
Bosworth BP
,
Scherl EJ
,
Sockolow R
. 2015.
Cerebral venous thrombosis in inflammatory bowel disease.
.
J Dig Dis. 16(2):104-8.
Weinstock LB
,
Bosworth BP
,
Scherl EJ
,
Li E
,
Iroku U
,
Munsell MA
,
Mullen GE
,
Walters AS
. 2010.
Crohn's disease is associated with restless legs syndrome.
.
Inflamm Bowel Dis. 16(2):275-9.
Dogan B
,
Belcher-Timme HFacey
,
Dogan EI
,
Jiang Z-D
,
Dupont HL
,
Snyder N
,
Yang S
,
Chandler B
,
Scherl EJ
,
Simpson KW
. 2018.
Evaluation of Escherichia coli pathotypes associated with irritable bowel syndrome.
.
FEMS Microbiol Lett. 365(22)
Castellanos JG
,
Woo V
,
Viladomiu M
,
Putzel G
,
Lima S
,
Diehl GE
,
Marderstein AR
,
Gandara J
,
Perez AR
,
Withers DR
et al.
. 2018.
Microbiota-Induced TNF-like Ligand 1A Drives Group 3 Innate Lymphoid Cell-Mediated Barrier Protection and Intestinal T Cell Activation during Colitis.
.
Immunity. 49(6):1077-1089.e5.
Dassopoulos T
,
Cohen RD
,
Scherl EJ
,
Schwartz RM
,
Kosinski L
,
Regueiro MD
. 2015.
Ulcerative Colitis Care Pathway.
.
Gastroenterology. 149(1):238-45.
Panaccione R
,
Danese S
,
Sandborn WJ
,
O'Brien CD
,
Zhou Y
,
Zhang H
,
Adedokun OJ
,
Tikhonov I
,
Targan S
,
Abreu MT
et al.
. 2020.
Ustekinumab is effective and safe for ulcerative colitis through 2 years of maintenance therapy.
.
Aliment Pharmacol Ther. 52(11-12):1658-1675.